What it does
The networking and cyber division offers telecoms and network solutions, focusing on advanced software and cybersecurity, to tier 1 businesses and governments worldwide.
The bio-medical division focuses on the development and provision of diagnostic lab equipment as well as products to treat biological waste products from the medical, agricultural, and pharmaceutical sectors.
The group is listed on the main board of the London Stock Exchange and is headquartered in Israel with offices in North America, Europe, and the Far East.
How is it doing
BATM recently launched three coronavirus testing kits - two to diagnose current cases and an antibody test to prove whether someone has had the disease before.
The firm has been ramping up production to meet higher demand, however it said it is too early to estimate financial performance for 2020.
In April BATM received a €29mln (£26mln) order to deliver 1,000 critical care mechanical ventilators to a European government.
What the boss says: Zvi Marom, chief executive
“Since the beginning of the [coronavirus] outbreak, we have been consistently launching more and more tools as soon as they were rigorously validated and certified by relevant regulatory authorities.”
"The serologic tests are now being provided to our customers at a time when they are most needed - to provide statistical information to decision-makers. This, together with our other innovative initiatives, will help health authorities in preparing for a potential second wave of [coronavirus] in the winter months.”
- Growth in testing kits production and sales
- More coronavirus-related orders